These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34994592)

  • 1. Patient With Stage IV NSCLC and CNS Metastasis With EGFR Exon 18-25 Kinase Domain Duplication With Response to Osimertinib as a First-Line Therapy.
    Taek Kim J; Zhang W; Lopategui J; Vail E; Balmanoukian A
    JCO Precis Oncol; 2021 Nov; 5():88-92. PubMed ID: 34994592
    [No Abstract]   [Full Text] [Related]  

  • 2. Osimertinib confers potent binding affinity to EGFR kinase domain duplication.
    Jin R; Li J; Jin Z; Lu Y; Shao YW; Li W; Zhao G; Xia Y
    Int J Cancer; 2019 Nov; 145(10):2884-2885. PubMed ID: 31393596
    [No Abstract]   [Full Text] [Related]  

  • 3. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
    van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
    Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations.
    Ikari T; Sakakibara-Konishi J; Yamamoto G; Kitai H; Mizugaki H; Asahina H; Kikuchi E; Shinagawa N
    Clin Lung Cancer; 2019 Jul; 20(4):e531-e533. PubMed ID: 31164318
    [No Abstract]   [Full Text] [Related]  

  • 5. Osimertinib in Resected
    Wu YL; Tsuboi M; He J; John T; Grohe C; Majem M; Goldman JW; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Hodge R; Atasoy A; Rukazenkov Y; Herbst RS;
    N Engl J Med; 2020 Oct; 383(18):1711-1723. PubMed ID: 32955177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib 160 mg daily for advanced non-small cell lung cancer with leptomeningeal metastasis: A case report.
    Tsang MW
    Asia Pac J Clin Oncol; 2019 Oct; 15 Suppl 6():5-7. PubMed ID: 31642175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
    Jänne PA; Planchard D; Kobayashi K; Cheng Y; Lee CK; Valdiviezo N; Laktionov K; Yang TY; Yu Y; Kato T; Jiang L; Chewaskulyong B; Lucien Geater S; Maurel JM; Rojas C; Takahashi T; Havel L; Shepherd FA; Tanaka K; Ghiorghiu D; Amin NP; Armenteros-Monterroso E; Huang X; Chaudhry AA; Yang JC
    J Clin Oncol; 2024 Mar; 42(7):808-820. PubMed ID: 38042525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).
    Vaid AK; Gupta A; Momi G
    Int J Oncol; 2021 Feb; 58(2):171-184. PubMed ID: 33491758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
    Cho JH; Lim SH; An HJ; Kim KH; Park KU; Kang EJ; Choi YH; Ahn MS; Lee MH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    J Clin Oncol; 2020 Feb; 38(5):488-495. PubMed ID: 31825714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis.
    Xing P; Mu Y; Hao X; Wang Y; Li J
    Clin Transl Oncol; 2019 Oct; 21(10):1424-1431. PubMed ID: 30864019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    Liu J; Jin B; Su H; Qu X; Liu Y
    BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy.
    Jelinek MJ; Armstrong SA; Patel JD; Subramaniam DS
    Clin Lung Cancer; 2019 Nov; 20(6):e597-e600. PubMed ID: 31542322
    [No Abstract]   [Full Text] [Related]  

  • 13. Osimertinib for
    Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
    Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.
    Ichihara E; Hotta K; Ninomiya K; Kubo T; Ohashi K; Rai K; Tanaka H; Tabata M; Maeda Y; Kiura K
    Lung Cancer; 2019 Jun; 132():54-58. PubMed ID: 31097094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.
    Remon J; Steuer CE; Ramalingam SS; Felip E
    Ann Oncol; 2018 Jan; 29(suppl_1):i20-i27. PubMed ID: 29462255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
    Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
    Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinomatosis under control by osimertinib in
    Provenzano L; Cuccarini V; Platania M; Canziani L; Spagnoletti A; Doniselli FM; Eoli M; Prelaj A; Anghileri E
    Tumori; 2021 Dec; 107(6):NP136-NP140. PubMed ID: 34727807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
    Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer.
    Ricciuti B; Chiari R; Chiarini P; Crinò L; Maiettini D; Ludovini V; Metro G
    Clin Drug Investig; 2016 Aug; 36(8):683-6. PubMed ID: 27177916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.